Investor Update

16 October 2023
Disclaimer

This document contains forward-looking statements, estimates, opinions and projections with respect to anticipated future performance of Atos SE (the “Company”) and its subsidiaries (together with the Company, the “Group”). These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will” or “should” or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include statements that may relate to Atos’s plans, objectives, strategies, goals, future events, future revenues or synergies, or performance, and other information that is not historical facts, including, without limitation, statements regarding the entry into final agreements in connection with the sale of TFCO and the consummation of the contemplated transaction, statements regarding market opportunities and forecasts regarding market trends, and statements regarding the anticipated performance of the Company post completion of the contemplated transaction.

Forward-looking statements are based on the current views, expectations and assumptions regarding the contemplated transaction, the business, the economy and other future conditions of the Company and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Factors that may cause actual results to differ materially from those contemplated by forward-looking statements, include, without limitation, the inability of the Company to successfully negotiate final agreements in connection with the sale of TFCO or to successfully or timely consummate the contemplated transaction, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to uncontrollable events that could adversely affect the Company or the contemplated transaction; failure to realize the anticipated benefits of the contemplated transaction; risks relating to the ability of the Company to issue equity securities or obtain debt financing in connection with the contemplated transaction or in the future.

Any forward-looking statements made in this document are statements about Atos’s beliefs and expectations and should be evaluated as such. Although the Company believes that these statements are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including matters not yet known to it or its management or not currently considered material, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. More detailed information on the potential risks that that could cause actual results to differ materially from the results anticipated in the forward-looking statements can be found in the 2022 Universal Registration Document filed with the Autorité des marchés financiers (AMF) on April 21, 2023 under the registration number D.23-0321.

Any forward-looking statements included herein only speak as at the date of this press release. Atos does not undertake, and specifically disclaims, any obligation or responsibility to update or amend any of the information above except as otherwise required by law. Atos accepts no liability whatsoever in respect of the achievement of such forward-looking statements and assumptions.

This document includes information on specific contemplated or envisioned transactions that shall be considered as projects only. In particular, any decision relating to the projects mentioned in this document and their terms and conditions remain conditional on general market conditions and would be subject to the financial and other customary conditions and processes, including governance bodies and shareholders’ approval as well as consultation with the relevant employee representative bodies, in accordance with applicable laws and regulations.

This document is provided for information purposes only. This document does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

This document is not a prospectus within the meaning of Regulation (UE) 2017/1129 of the European Parliament and of the Council of 14 June 2017 as amended (the “Prospectus Regulation”) and as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (the “UK Prospectus Regulation”). With respect to the member States of the European Economic Area and the United Kingdom (each a “Relevant State”), securities may not be offered or sold absent the publication of a prospectus in any Relevant Member State or in the United Kingdom or an exemption from such publication under the Prospectus Regulation or the UK Prospectus Regulation.

This document does not constitute or form part of any offer of securities for sale or a solicitation of an offer to purchase or to subscribe securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any State or other jurisdiction of the United States, and may not be offered or sold in the United States absent registration under the Securities Act or pursuant to an exemption from such registration. Atos SE does not intend to register all or any portion of its securities in the United States under the Securities Act or to conduct a public offering of the Securities in the United States.
Key investor messages

• Change in Group governance: – Jean-Pierre Mustier appointed Chairman of the Board
  – Laurent Collet-Billon appointed Vice Chairman

• Separation of Tech Foundations and Eviden would unlock the intrinsic value of Eviden and reflects the different dynamics of the two businesses

• Contemplated sale of Tech Foundations presented on August 1, 2023 offers the most achievable execution path to the separation of Tech Foundations and Eviden

• Regulatory approval and social process underway

• Ongoing discussions with EPEI on certain transaction parameters

• Shareholder meeting to vote on transaction and capital raise anticipated in early Q2 2024

• Active discussions with financing banks to obtain loan waivers and secure new financing for Eviden should the deal with EPEI happen

• Should the transaction with EPEI not go forward, the Group will have to access the debt and equity capital markets and/or consider the sale of additional assets, to ensure adequate liquidity to address upcoming debt maturities in 2025

• Commitment to ongoing regular dialogue with shareholders
Atos operates in two distinct markets with fundamentally different dynamics.

<table>
<thead>
<tr>
<th>2022 Revenue and Operating Margin</th>
<th>Tech Foundations</th>
<th>Eviden</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2022 Revenue and Operating Margin</strong></td>
<td>€6.0bn revenue: 53% of total Group</td>
<td>€5.3bn revenue: 47% of total Group</td>
</tr>
<tr>
<td></td>
<td>€79m Operating Margin: 1.3% of TFCo revenue</td>
<td>€276m Operating Margin: 5.2% of Eviden revenue</td>
</tr>
<tr>
<td><strong>Segments</strong></td>
<td>Technology Services, Cloud &amp; Infrastructure, Digital Business Platforms, Digital Workplace</td>
<td>Advanced Computing, Digital Security, Cloud, Smart Platforms, Gen-AI</td>
</tr>
<tr>
<td><strong>Market and Dynamics</strong></td>
<td>€705bn Global Infra &amp; Private Cloud Market (2022)</td>
<td>€1.8tn Global Digital, Big Data &amp; Security Market (2026)</td>
</tr>
<tr>
<td></td>
<td>Low single digit growth</td>
<td>Double digit LT growth</td>
</tr>
<tr>
<td></td>
<td>A mature market segment, shifting from traditional to next-gen infrastructure</td>
<td></td>
</tr>
<tr>
<td><strong>Mid-term OM</strong></td>
<td>Mid-High single digit</td>
<td>Low double digits</td>
</tr>
<tr>
<td><strong>Focus</strong></td>
<td>Stabilizing revenue and delivering positive cash flow</td>
<td>Growth and margin acceleration</td>
</tr>
</tbody>
</table>
Strategic rationale for separating the businesses

- Unlocking the *inherent intrinsic value* of Eviden
- Greater *agility to execute* tailored strategy of the distinct businesses
- *Operating model of each business* tailored to *customer needs*
- Allow each company to *invest in their core capabilities*
- Ensure each business has an *appropriate capital structure*
Rationale for pursuing the contemplated transaction

- Since the announcement of the separation plan in June 2022, Atos was approached by several players interested in the acquisition of the Tech Foundations business.
- The Group and its Board examined all received expressions of interest in light of the Group’s corporate interest.
- The contemplated transaction was determined to offer the most achievable execution plan for the separation of Tech Foundation and Eviden.
- The contemplated transaction improves the risk profile of the Group post transaction.
- Economic and capital market conditions made it increasingly challenging to monetize Eviden on acceptable terms and access the financing market for Tech Foundations.
Key milestones associated with the contemplated transaction

Steps

- Regulatory filing and Social plans
- Negotiation with Banks
- Proforma financials
- Signing of Share Purchase Agreement (SPA)
- Shareholder meeting
- Capital Increase
### Key milestones associated with the contemplated transaction

<table>
<thead>
<tr>
<th>Steps</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regulatory filing and Social plans</td>
<td>Filed in most jurisdictions, solid progress;</td>
</tr>
<tr>
<td></td>
<td>Social consultation with the Societas European Council (SEC) and at</td>
</tr>
<tr>
<td></td>
<td>local level ongoing</td>
</tr>
<tr>
<td>Negotiation with Banks</td>
<td>Active discussions underway:</td>
</tr>
<tr>
<td></td>
<td>• Positive feedback for obtaining waivers</td>
</tr>
<tr>
<td></td>
<td>• Negotiations of debt refinancing ongoing</td>
</tr>
<tr>
<td>Proforma financials</td>
<td>FY22 and H1 23 proforma financials being drawn up</td>
</tr>
<tr>
<td>Signing of Share Purchase Agreement (SPA)</td>
<td>Ongoing discussion on certain transaction parameters,</td>
</tr>
<tr>
<td></td>
<td>Final agreements targeted to be completed by the end of 2023</td>
</tr>
<tr>
<td>Shareholder meeting</td>
<td>To approve both the proposed sale of Tech Foundations and the Capital increases Anticipated in early Q2 2024</td>
</tr>
<tr>
<td>Capital Increase</td>
<td>As soon as practicable after Shareholder meeting</td>
</tr>
</tbody>
</table>
Transaction overview

**Contemplated TFCo sale to EPEI**

- €0.1bn net positive cash proceeds for Eviden
- €1.9bn transfer of on-balance sheet liabilities
- Transfer of €7.6bn of off-balance sheet liabilities
- Conveyance of €0.8bn of working capital attributable to Tech Foundations
- Deconsolidation of Tech Foundations negative FCF
- Upside-sharing mechanism for Eviden
- EPEI group to capitalize a Special Purpose Vehicle with €0.8bn at closing to acquire TFCo

**Strengthen Eviden capital structure**

- Contemplated capital increase of €900m:
  - €180m reserved capital from EPEI at 20€ per share, in exchange of a 7.5% stake
  - €720m of rights offering
  - Standby underwriting provided by BNP Paribas and J.P. Morgan for the rights issue subject to usual conditions
- €400m divestment plan
- Target Eviden proforma net leverage of ca.4x improving to ca.2x by end of 2025
Transaction overview

Contemplated TFCo sale to EPEI

- €0.1bn net positive cash proceeds for Eviden
- €1.9bn transfer of on-balance sheet liabilities
- Transfer of €7.6bn of off-balance sheet liabilities
- Conveyance of €0.8bn of working capital attributable to Tech Foundations
- Deconsolidation of Tech Foundations negative FCF
- Upside-sharing mechanism for Eviden
- EPEI group to capitalize a Special Purpose Vehicle with €0.8bn at closing to acquire TFCo

Strengthen Eviden capital structure

- Contemplated capital increase of €900m:
  - €180m reserved capital from EPEI at 20€ per share, in exchange of a 7.5% stake
  - €720m of rights offering
  - Standby underwriting provided by BNP Paribas and J.P. Morgan for the rights issue subject to usual conditions
- €400m divestment plan
- Target Eviden proforma net leverage of ca.4x improving to ca.2x by end of 2025
**Transaction overview**

**Contemplated TFCo sale to EPEI**

- €0.1bn net positive cash proceeds for Eviden
- €1.9bn transfer of on-balance sheet liabilities
- Transfer of €7.6bn of off-balance sheet liabilities
- Conveyance of €0.8bn of working capital attributable to Tech Foundations
- Deconsolidation of Tech Foundations negative FCF
- Upside-sharing mechanism for Eviden
- EPEI group to capitalize a Special Purpose Vehicle with €0.8bn at closing to acquire TFCo

**Mechanism for net cash proceeds**

- All receivables and payables attributable to Tech Foundations to be conveyed to TFCo at closing
- SPA agreement with EPEI allows the Group to monetize €442m of receivables thru factoring
- Out of €442m in cash proceeds from factoring, Eviden entitled to €104m net cash proceeds; the balance to remain with TFCo in the form of:
  - €250m of cash on the balance sheet
  - €88m of cash compensation for the transfer of risks and charges
- EPEI to pay €1 for shares of TFCo
Transaction overview

Contemplated TFCo sale to EPEI

• €0.1bn net positive cash proceeds for Eviden
• €1.9bn transfer of on-balance sheet liabilities
• Transfer of €7.6bn of off-balance sheet liabilities
• Conveyance of €0.8bn of working capital attributable to Tech Foundations
• Deconsolidation of Tech Foundations negative FCF
• Upside-sharing mechanism for Eviden
• EPEI group to capitalize a Special Purpose Vehicle with €0.8bn at closing to acquire TFCo

<table>
<thead>
<tr>
<th>Elements of on-balance sheet liabilities in €bn</th>
<th>Dec 2022</th>
<th>Jun 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provisions for risks and charges</td>
<td>0.6</td>
<td>0.6</td>
</tr>
<tr>
<td>Lease liabilities (IFRS 16)</td>
<td>0.8</td>
<td>0.7</td>
</tr>
<tr>
<td>Pension provisions</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Other and contingencies</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1.9</strong></td>
<td><strong>1.8</strong></td>
</tr>
</tbody>
</table>

Transfer of on-balance sheet liabilities to significantly reduce the Group risk profile

Dec 2022  Jun 2023
Transaction overview

Contemplated TFCo sale to EPEI

- €0.1bn net positive cash proceeds for Eviden
- €1.9bn transfer of on-balance sheet liabilities
- Transfer of €7.6bn of off-balance sheet liabilities
- Conveyance of €0.8bn of working capital attributable to Tech Foundations
- Deconsolidation of Tech Foundations negative FCF
- Upside-sharing mechanism for Eviden
- EPEI group to capitalize a Special Purpose Vehicle with €0.8bn at closing to acquire TFCo

Elements of off-balance sheet liabilities

<table>
<thead>
<tr>
<th>Guarantee Type</th>
<th>Dec, 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Performance guarantees</td>
<td>4.8</td>
</tr>
<tr>
<td>Leasing guarantees</td>
<td>0.4</td>
</tr>
<tr>
<td>Financing guarantees</td>
<td>0.4</td>
</tr>
<tr>
<td>Other parent company guarantees</td>
<td>2.0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>7.6</strong></td>
</tr>
</tbody>
</table>

Transfer of off-balance sheet liabilities to significantly reduce the Group risk profile
Contemplated TFCo sale to EPEI

- €0.1bn net positive cash proceeds for Eviden
- €1.9bn transfer of on-balance sheet liabilities
- Transfer of €7.6bn of off-balance sheet liabilities
- Conveyance of €0.8bn of working capital attributable to Tech Foundations
- Deconsolidation of Tech Foundations negative FCF
- Upside-sharing mechanism for Eviden
- EPEI group to capitalize a Special Purpose Vehicle with €0.8bn at closing to acquire TFCo

Working capital (WC):
- Current operating assets less current liabilities
- As of August 1, 2023 WC to run TFCo estimated at ca. €0.8bn: to be conveyed to buyer at closing
- WC actions include:
  - Non-recourse factoring
  - Reduction of avg. payment period of trade receivables
  - Extended supplier payment terms
- TFCo WC after WC actions forecasted at €(0.2bn) as on December 31, 2023

Conveying €0.8bn WC at closing, which includes current operating assets and liabilities attributable to TFCo, represents ca. €1bn difference with the forecasted WC of €(0.2bn)

€1.0bn difference does not represent cash paid by Eviden to TFCo
Transaction overview

**Contemplated TFCo sale to EPEI**

- €0.1bn net positive cash proceeds for Eviden
- €1.9bn transfer of on-balance sheet liabilities
- Transfer of €7.6bn of off-balance sheet liabilities
- Conveyance of €0.8bn of working capital attributable to Tech Foundations
- Deconsolidation of Tech Foundations negative FCF
- Upside-sharing mechanism for Eviden
- EPEI group to capitalize a Special Purpose Vehicle with €0.8bn at closing to acquire TFCo

*Significant negative free cash flow of TFCo in 2023 and 2024 due to:*

- Restructuring
- Consolidation of data centers
- Vendor commitments
- Red accounts
Transaction overview

Contemplated TFCo sale to EPEI

- €0.1bn net positive cash proceeds for Eviden
- €1.9bn transfer of on-balance sheet liabilities
- Transfer of €7.6bn of off-balance sheet liabilities
- Conveyance of €0.8bn of working capital attributable to Tech Foundations
- Deconsolidation of Tech Foundations negative FCF
- Upside-sharing mechanism for Eviden
- EPEI group to capitalize a Special Purpose Vehicle with €0.8bn at closing to acquire TFCo

- Eviden entitled to receive up to 10% of TFCo’s share capital in 2027 depending on the achievement of certain operational targets
- In case of total or partial monetization of TFCo by EPEI, Eviden would receive
  - 40% of net proceeds of such transaction before December 31, 2026 and
  - 20% of net proceeds from January 1st 2027 to December 31, 2028
Transaction overview

Contemplated TFCo sale to EPEI

• €0.1bn net positive cash proceeds for Eviden
• €1.9bn transfer of on-balance sheet liabilities
• Transfer of €7.6bn of off-balance sheet liabilities
• Conveyance of €0.8bn of working capital attributable to Tech Foundations
• Deconsolidation of Tech Foundations negative FCF
• Upside-sharing mechanism for Eviden
• EPEI group to capitalize a Special Purpose Vehicle with €0.8bn at closing to acquire TFCo
Transaction overview

Contemplated TFCo sale to EPEI

• €0.1bn net positive cash proceeds for Eviden
• €1.9bn transfer of on-balance sheet liabilities
• Transfer of €7.6bn of off-balance sheet liabilities
• Conveyance of €0.8bn of working capital attributable to Tech Foundations
• Deconsolidation of Tech Foundations negative FCF
• Upside-sharing mechanism for Eviden
• EPEI group to capitalize a Special Purpose Vehicle with €0.8bn at closing to acquire TFCo

Strengthen Eviden capital structure

• Contemplated capital increase of €900m:
  – €180m reserved capital from EPEI at 20€ per share, in exchange of a 7.5% stake
  – €720m of rights offering
    – Standby underwriting provided by BNP Paribas and J.P. Morgan for the rights issue subject to usual conditions
• €400m divestment plan
• Target Eviden proforma net leverage of ca.4x improving to ca.2x by end of 2025
Transaction overview

Strengthen Eviden capital structure

- Contemplated capital increase of €900m:
  - €180m reserved capital from EPEI at 20€ per share, in exchange of a 7.5% stake
  - €720m of rights offering
  - Standby underwriting provided by BNP Paribas and J.P. Morgan for the rights issue subject to usual conditions

- €400m divestment plan

- Target Eviden proforma net leverage of ca.4x improving to ca.2x by end of 2025
Transaction overview

**Strengthen Eviden capital structure**

- Contemplated capital increase of €900m:
  - €180m reserved capital from EPEI at 20€ per share, in exchange of a 7.5% stake
  - €720m of rights offering
    - Standby underwriting provided by BNP Paribas and J.P. Morgan for the rights issue subject to usual conditions
- €400m divestment plan
- Target Eviden proforma net leverage of ca.4x improving to ca.2x by end of 2025

- Announced on July 28, 2023
- Consists of non-strategic Eviden assets
- Signed one transaction already
- Signature and cash proceeds from remaining assets expected in FY24
Transaction overview

**Strengthen Eviden capital structure**

- Contemplated capital increase of €900m:
  - €180m reserved capital from EPEI at 20€ per share, in exchange of a 7.5% stake
  - €720m of rights offering
  - Standby underwriting provided by BNP Paribas and J.P. Morgan for the rights issue subject to usual conditions
- €400m divestment plan
- Target Eviden proforma net leverage of ca.4x improving to ca.2x by end of 2025
Eviden: Capital structure framework

Liquidity management
- **Strong Free Cash Flow**
- **Access to RCF facility**
- Maintain current RCF
- Secure new forward starting RCF (start in Nov 2025) (under negotiation)

Credit rating profile
- **S&P BB- indicative rating at closing**
- **Targeting investment grade credit rating**
- **Net reported leverage of ca. 3x by 2024 and ca. 2x by 2025**

Debt maturity
- **New term loan with lower principal maturing in Dec 2026** (under negotiation)
- **Access to debt market**
- **Balanced maturity ladder**

Current maturity profile, €m

<table>
<thead>
<tr>
<th>Fiscal year</th>
<th>2024</th>
<th>2025</th>
<th>2026</th>
<th>2027</th>
<th>2028</th>
<th>2029</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exchangable Bonds</td>
<td>500</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Existing Bonds</td>
<td></td>
<td>750</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Existing RCF</td>
<td></td>
<td></td>
<td>750</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Existing Bonds</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>350</td>
<td></td>
</tr>
<tr>
<td>Existing Bonds</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>800</td>
</tr>
</tbody>
</table>
**Eviden: Capital structure framework**

### Liquidity management
- **Strong Free Cash Flow**
- **Access to RCF facility**
  - Maintain current RCF
  - Secure new forward starting RCF (start in Nov 2025) (under negotiation)

### Credit rating profile
- **S&P BB- indicative rating at closing**
- **Targeting investment grade credit rating**
- **Net reported leverage of ca. 3x by 2024 and ca. 2x by 2025**

### Debt maturity
- **New term loan with lower principal maturing in Dec 2026** (under negotiation)
- **Access to debt market**
- **Balanced maturity ladder**

### Target maturity profile, €m

<table>
<thead>
<tr>
<th>Fiscal year</th>
<th>Exchangable Bonds</th>
<th>Existing Bonds</th>
<th>Existing RCF</th>
<th>New TL</th>
<th>New fwd. start RCF</th>
<th>Existing Bonds</th>
<th>Existing Bonds</th>
</tr>
</thead>
<tbody>
<tr>
<td>2024</td>
<td>500</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2025</td>
<td></td>
<td>750</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2026</td>
<td></td>
<td></td>
<td>New TL</td>
<td></td>
<td></td>
<td>350</td>
<td>800</td>
</tr>
<tr>
<td>2027</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2026</td>
<td>350</td>
<td></td>
</tr>
<tr>
<td>2028</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2028</td>
<td></td>
</tr>
<tr>
<td>2029</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2029</td>
<td></td>
</tr>
</tbody>
</table>
Liquidity plan

• Should the contemplated transaction and capital raise be approved by shareholders:
  Eviden expected to have necessary liquidity to run its business driven by:
  – Access to capital market
  – Assuming capital increase and new term loan from financing banks

• Should the contemplated transaction not move forward:
  Group expects to meet its liquidity requirements for 2024 driven by:
  – Forecasted business performance
  – Assuming continued access to the factoring program and completion of the €0.4bn asset divestment plan announced on July 28, 2023
  – Group would have to access the debt and equity capital markets and/or consider the sale of additional assets to refinance €1.5bn TL A maturing in January 2025 and €750m bonds maturing in May 2025
Accounting matters

- Proforma financials of Tech Foundations and Eviden are currently being drawn up
- Annual impairment test that the Group carries out at year end could lead to significant impairment charge. Among the factors:
  - Contemplated transaction regarding Tech Foundations
  - Atos share price, should it remain at current levels
Key investor messages

• Change in Group governance: – Jean-Pierre Mustier appointed Chairman of the Board
  – Laurent Collet-Billon appointed Vice Chairman

• Separation of Tech Foundations and Eviden would unlock the intrinsic value of Eviden and reflects
  the different dynamics of the two businesses

• Contemplated sale of Tech Foundations presented on August 1, 2023 offers the most achievable
  execution path to the separation of Tech Foundations and Eviden

• Regulatory approval and social process underway

• Ongoing discussions with EPEI on certain transaction parameters

• Shareholder meeting to vote on transaction and capital raise anticipated in early Q2 2024

• Active discussions with financing banks to obtain loan waivers and secure new financing for Eviden
  should the deal with EPEI happen

• Should the transaction with EPEI not go forward, the Group will have to access the debt and equity
  capital markets and/or consider the sale of additional assets, to ensure adequate liquidity to
  address upcoming debt maturities in 2025

• Commitment to ongoing regular dialogue with shareholders